Hims & Hers price target raised to $29 from $25 at Barclays
Barclays analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $29 from $25 and keeps an Overweight rating on the shares. The rally post the Novo Nordisk agreement highlights the incremental market opportunity and removal of the legal overhang for Hims & Hers shares, the analyst tells investors in a research note. Barclays believes the market is still underappreciating Hims’ opportunity from new products.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
See Insiders’ Hot Stocks on TipRanks >>
Read More on HIMS:
- HIMS-Novo ‘Can’t Quit Each Other’ – Bulls Rally on Wegovy Deal
- Hims & Hers names Kathryn Beiser as Chief Communications Officer
- Hims & Hers rises 12.0%
- Unusually active option classes on open March 10th
- Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3 Altcoins to Watch in the First Week of November 2026
Trump and Jim Cramer Defend SpaceX as Musk Wants to Enter the Telecom Market
Gold’s lost haven allure to swing back into view on deficit woes
Crypto prices
More
